Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Redundancy of Glycogen Synthase Kinase 3 in Lymphoma Cell Viability, Proliferation, and the Cytotoxicity of Elraglusib

Josh T Coats, Sudhir Tauro, Calum Sutherland

Blood (2023) 142 (Supplement 1): 5802.

https://doi.org/10.1182/blood-2023-173124

Published: 2023

Journal Articles

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Blood (2020) 136 (2): 157–170.

https://doi.org/10.1182/blood.2020004850

Published: 2020

Journal Articles

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Blood (2016) 128 (16): 2096–2097.

https://doi.org/10.1182/blood-2016-07-728766

Published: 2016

Journal Articles

Time-dependent changes in mortality and transformation risk in MDS

Blood (2016) 128 (7): 902–910.

https://doi.org/10.1182/blood-2016-02-700054

Published: 2016

Includes: Supplemental data

Journal Articles

Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

Blood (2015) 126 (23): 907.

https://doi.org/10.1182/blood.V126.23.907.907

Published: 2015

Journal Articles

Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes

Blood (2015) 126 (23): 2879.

https://doi.org/10.1182/blood.V126.23.2879.2879

Published: 2015

Journal Articles

TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee

Blood (2014) 124 (21): 532.

https://doi.org/10.1182/blood.V124.21.532.532

Published: 2014

Journal Articles

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Blood (2013) 122 (22): 3616–3627.

https://doi.org/10.1182/blood-2013-08-518886

Published: 2013

Includes: Supplemental data

Journal Articles

Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age

Blood (2013) 122 (21): 1544.

https://doi.org/10.1182/blood.V122.21.1544.1544

Published: 2013

Journal Articles

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Jyoti Nangalia, MBBChir FRCPath, Charles Massie, PhD, E Joanna Baxter, PhD, Francesca L Nice, MRes, Gunes Gundem, PhD, David Wedge, PhD, Edward Avezov, PhD, Juan Li, PhD, Karoline Kollmann, PhD, David G. Kent, PhD, Athar Aziz, PhD, Anna L Godfrey, BMBCh FRCPath, Jonathan Hinton, MSc, Inigo Martincorena, PhD, Peter Van Loo, PhD, Amy V Jones, PhD, Paola Guglielmelli, PhD MD, Patrick Tarpey, PhD, Heather P Harding, PhD, John D Fitzpatrick, BA, Calum T Goudie, BA, Christina A Ortmann, MD, Stephen J Loughran, PhD, Keiran Raine, MSc, David Jones, MSc, Adam Butler, MSc, Jon W Teague, MSc, Sarah O'Meara, Stuart McLaren, Michele Bianchi, Yvonne Silber, MSc, Danai Dimitropolou, BSc, David Bloxham, MSc FRCPath, Laura J Mudie, BSc, Mark Maddison, BSc, Ben Robinson, BSc, Clodagh Keohane, MD, Cathy MacLean, MSc, Kate Hill, BM BS, Kim H. Orchard, MBBS, PhD, FRCP, FRCPath, Sudhir Tauro, PhD, Ming-Qing Du, MB, PhD, Mel Greaves, PhD, FRS, David Bowen, MD, PhD, Brian Huntly, MBChB FRCPath PhD, Claire N Harrison, DM, FRCP, FRCPath, Nicholas C.P. Cross, PhD, FRCPath, David Ron, MD, Alessandro M Vannucchi, MD, Elli Papaemmanuil, PhD, Peter J. Campbell, PhD, Anthony R Green, FRCPath FMedSci

Blood (2013) 122 (21): LBA-2.

https://doi.org/10.1182/blood.V122.21.LBA-2.LBA-2

Published: 2013

Journal Articles

High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic

Elli Papaemmanuil, PhD, Moritz Gerstung, PhD, Luca Malcovati, MD, Sudhir Tauro, PhD, Gunes Gundem, PhD, Peter Van Loo, PhD, Andrea Pellagatti, PhD, Michael J Groves, PhD, Nick C.P. Cross, PhD, Carlo Gambacorti-Passerini, MD, Anthony R Green, MD, Jacqueline Boultwood, PhD, Paresh Vyas, MD, Eva Hellstrom-Lindberg, MD, David Bowen, MD, Mario Cazzola, MD, Michael R Stratton, MD, PhD, Peter Campbell, MD Phd

Blood (2012) 120 (21): LBA-5.

https://doi.org/10.1182/blood.V120.21.LBA-5.LBA-5

Published: 2012

Journal Articles

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Blood (2012) 120 (12): 2454–2465.

https://doi.org/10.1182/blood-2012-03-420489

Published: 2012

Includes: Supplemental data

Journal Articles

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Blood (2011) 118 (24): 6239–6246.

https://doi.org/10.1182/blood-2011-09-377275

Published: 2011

Includes: Supplemental data

Journal Articles

Somatic Mutation of SF3B1 , a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts

Blood (2011) 118 (21): 3.

https://doi.org/10.1182/blood.V118.21.3.3

Published: 2011

Journal Articles

Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group

Michal Sieniawski, Jennifer Wilkinson, Dominic Culligan, John Davies, John Goodlad, Ruth Jarrett, Anne L Lennard, Helen Lucraft, Tryfonia Mainou-Fowler, Pam McKay, Fiona Scott, Sudhir Tauro, Jo White, Stephen J Proctor

Blood (2008) 112 (11): 2604.

https://doi.org/10.1182/blood.V112.11.2604.2604

Published: 2008

Journal Articles

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Emmanouil Nikolousis, Charles F. Craddock, BM, MRCP, MRCPath, Shankaranarayana Paneesha, MD, Sudhir Tauro, Prem Mahendra, II, Mark Cook, Fiona Clark, Richard Lovell, Sridhar Chaganti, Donald Milligan, MD, MBChB, Dominique Mcmullan, Mike Griffiths, Stephen P Robinson, MD

Blood (2008) 112 (11): 4409.

https://doi.org/10.1182/blood.V112.11.4409.4409

Published: 2008

Journal Articles

Factors Predicting Long Term Survival after Reduced Intensity Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia.

Charles F. Craddock, MD, PhD, Sudhir Tauro, MDPhD, Joanne E. Gregory, Laura Buckley, PhD, Janice Ward, BSc(Hons), Panos Kottaridis, MDPhD, Eleni Thelouli, MDPhD, Kirsty Thomson, MDPhD, Donald Milligan, MDPhD, Emma Das-Gupta, MDPhD, Effie Liakpopoulou, MDPhD, John Snowden, MDPhD, John Yin, MDPhD, Andrew Peniket, MDPhD, Mark Cook, MDPhD, Stephen MacKinnon, MDPhD, Nigel H. Russell, MDPhD

Blood (2007) 110 (11): 326.

https://doi.org/10.1182/blood.V110.11.326.326

Published: 2007

Journal Articles

Intensifying Methotrexate (MTX) Dosage Reduces Treatment Failure in Adults with Burkitt or Burkitt-Like Leukaemia/Lymphoma (BL) Treated with an Adapted BFM Protocol.

Sudhir Tauro, Gulnaz Begum, Grete Fossum Lauritzsen, Jan Delabie, Claudia Roberts, Premini Mahendra, Harald Holte

Blood (2006) 108 (11): 2438.

https://doi.org/10.1182/blood.V108.11.2438.2438

Published: 2006

Journal Articles

Identification of Novel Signalling Pathways in Myeloblasts from Patients with Acute Myeloid Leukemia Using a Phosphoproteomic Strategy.

Charles Craddock, MD, PhD, Sudhir Tauro, MD, PhD, Michael Griffiths, PhD, Mark Cook, MD, PhD, Harprit Singh, PhD, Michael Wakelam, PhD

Blood (2005) 106 (11): 670.

https://doi.org/10.1182/blood.V106.11.670.670

Published: 2005

Journal Articles

Direct Adoptive Transfer of Cytomegalovirus-Specific CTL from Unrelated Donors to Stem Cell Transplant Patients Following Selection by HLA-Peptide Tetramers.

Mark Cobbold, MD, PhD, Persis Amrolia, MD, PhD, Prem Mahendra, MD, PhD, Colin Steward, MD, PhD, Eduardo Olavarria, MD, PhD, Julie Arrazi, Dorothy McDonald, PhD, Sudhir Tauro, MD, PhD, John Goldman, MD, PhD, Charles Craddock, MD, PhD, Paul Moss, MD, PhD

Blood (2004) 104 (11): 155.

https://doi.org/10.1182/blood.V104.11.155.155

Published: 2004

NARROW

Redundancy of Glycogen Synthase Kinase 3 in Lymphoma Cell Viability, Proliferation, and the Cytotoxicity of Elraglusib

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Time-dependent changes in mortality and transformation risk in MDS

Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes

TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Somatic Mutation of SF3B1 , a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts

Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Factors Predicting Long Term Survival after Reduced Intensity Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia.

Intensifying Methotrexate (MTX) Dosage Reduces Treatment Failure in Adults with Burkitt or Burkitt-Like Leukaemia/Lymphoma (BL) Treated with an Adapted BFM Protocol.

Identification of Novel Signalling Pathways in Myeloblasts from Patients with Acute Myeloid Leukemia Using a Phosphoproteomic Strategy.

Direct Adoptive Transfer of Cytomegalovirus-Specific CTL from Unrelated Donors to Stem Cell Transplant Patients Following Selection by HLA-Peptide Tetramers.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only